drugset / Trial / NCT02935634

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

NCT02935634 ↗

Phase 2 Completed 190 enrolled Bristol-Myers Squibb Clovis Oncology, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.

Timeline

Start
2016-11-29
Primary completion
2022-05-11
Completion
2022-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody — —
Subject LINRODOSTAT Small molecule — —
Subject Nivolumab Monoclonal antibody — —
Subject Relatlimab Monoclonal antibody — —
Subject Rucaparib Small molecule — —

Indications